CLYM
Climb Bio Inc.

213
Mkt Cap
$139.59M
Volume
334,740.00
52W High
$4.82
52W Low
$1.05
PE Ratio
-2.97
CLYM Fundamentals
Price
$1.99
Prev Close
$2.06
Open
$2.05
50D MA
$2.12
Beta
0.96
Avg. Volume
439,111.95
EPS (Annual)
-$1.53
P/B
0.75
Rev/Employee
$0.00
Loading...
Loading...
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
18

Frequently Asked Questions

What is Market Cap of Climb Bio Inc.?
What is the 52-week high for Climb Bio Inc.?
What is the 52-week low for Climb Bio Inc.?
What is Climb Bio Inc. stock price today?
What was Climb Bio Inc. stock price yesterday?
What is the PE ratio of Climb Bio Inc.?
What is the Price-to-Book ratio of Climb Bio Inc.?
What is the 50-day moving average of Climb Bio Inc.?
How many employess does Climb Bio Inc. has?

Latest CLYM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.